Sukumar Nagendran
Director; Director, President and Head of R&D · 3 filings · Latest: Jun 10, 2026
Solid Biosciences Inc.
Taysha Gene Therapies, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
TSHA | Sukumar Nagendran | Director, President and Head of R&D | Apr 10, 2026 | Sale | $4.46 | 200,000 | $892.0K | 1,136,410 | |
TSHA | Sukumar Nagendran | Director, President and Head of R&D | Apr 10, 2026 | Option Exercise | $1.71 | 19,021 | $32.5K | 1,336,410 | |
TSHA | Nagendran Sukumar | — | Apr 10, 2026 | Proposed Sale | $4.63 | 200,000 | $926.0K | — | |
TSHA | Sukumar Nagendran | Director, President and Head of R&D | Jan 26, 2026 | Sale | $4.61 | 26,918 | $124.1K | 1,317,389 | |
TSHA | Sukumar Nagendran | Director, President and Head of R&D | Jan 23, 2026 | Sale | $4.75 | 89,132 | $423.4K | 1,344,307 | |
TSHA | Sukumar Nagendran | — | Jan 23, 2026 | Proposed Sale | $5.09 | 113,824 | $579.4K | — | |
TSHA | Nagendran Sukumar | — | Jan 12, 2026 | Proposed Sale | $4.98 | 200,000 | $996.0K | — | |
TSHA | Nagendran Sukumar | — | Nov 28, 2025 | Proposed Sale | $4.86 | 370,172 | $1.8M | — | |
TSHA | Nagendran Sukumar | — | Sep 10, 2025 | Proposed Sale | $3.26 | 200,000 | $652.0K | — | |
TSHA | Sukumar Nagendran | — | Aug 21, 2025 | Proposed Sale | $2.87 | 57,054 | $163.7K | — |